Cargando…

CCDC103 as a Prognostic Biomarker Correlated with Tumor Progression and Immune Infiltration in Glioma

BACKGROUND: The Coiled-coil domain-containing proteins (CCDCs) are expressed in many cancers, but the role of Coiled-coil domain-containing protein 103 (CCDC103) in cancers remains unclear. Further investigations are necessary to ascertain its diagnostic significance and understand its biological fu...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Zhixing, Xu, Haitao, Chen, Xi, Huang, Xiaobing, Tian, Jintao, Zhao, Jinxi, Liu, Bohu, Shi, Fengcai, Wu, Jin, Pu, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590567/
https://www.ncbi.nlm.nih.gov/pubmed/37873495
http://dx.doi.org/10.2147/OTT.S429958
_version_ 1785124015933751296
author Xu, Zhixing
Xu, Haitao
Chen, Xi
Huang, Xiaobing
Tian, Jintao
Zhao, Jinxi
Liu, Bohu
Shi, Fengcai
Wu, Jin
Pu, Jun
author_facet Xu, Zhixing
Xu, Haitao
Chen, Xi
Huang, Xiaobing
Tian, Jintao
Zhao, Jinxi
Liu, Bohu
Shi, Fengcai
Wu, Jin
Pu, Jun
author_sort Xu, Zhixing
collection PubMed
description BACKGROUND: The Coiled-coil domain-containing proteins (CCDCs) are expressed in many cancers, but the role of Coiled-coil domain-containing protein 103 (CCDC103) in cancers remains unclear. Further investigations are necessary to ascertain its diagnostic significance and understand its biological function in cancers. This study aims to elucidate the biological functionalities of CCDC103 in glioma and evaluate the correlation between CCDC103 expression with glioma progression. METHODS: Clinical data on glioma patients were acquired from The Cancer Genome Atlas (TCGA), the Chinese Glioma Genome Atlas (CGGA), and the Gene Expression Omnibus (GEO). The evaluation encompassed the examination of correlations between CCDC103 expression, pathological characteristics, and clinical outcomes. Furthermore, the analysis included the assessment of the correlations between CCDC103 expression and immune cell infiltration as well as glioma progression. RESULTS: Gliomas have higher levels of CCDC103 expression than the para-carcinoma tissues. Poorer prognosis, unfavorable histological characteristics, the absence of IDH gene mutations, and the absence of chromosome 1p and 19q deletions were all associated with higher expression of CCDC103 in gliomas. In addition to patient age, tumor grade, the absence of IDH mutations, and the absence of chromosome 1p and 19q deletions, univariate and multivariate Cox analyses showed that CCDC103 expression was independently prognostic of overall survival, disease-free survival, and progression-free survival in patients with glioma. Furthermore, tumor infiltration of B cells, neutrophils, macrophages, and dendritic cells were all linked with elevated expression of CCDC103. High CCDC103 expression was linked to immune response-related signaling pathways and cell proliferation, according to gene set enrichment analysis (GSEA). Notably, the knockdown of CCDC103 in glioma cell lines resulted in a significant reduction in cell proliferation and migration. CONCLUSION: The correlation between CCDC103 expression and both glioma progression and immune cell infiltration implies that CCDC103 expression holds promise as a valuable prognostic biomarker for glioma.
format Online
Article
Text
id pubmed-10590567
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-105905672023-10-23 CCDC103 as a Prognostic Biomarker Correlated with Tumor Progression and Immune Infiltration in Glioma Xu, Zhixing Xu, Haitao Chen, Xi Huang, Xiaobing Tian, Jintao Zhao, Jinxi Liu, Bohu Shi, Fengcai Wu, Jin Pu, Jun Onco Targets Ther Original Research BACKGROUND: The Coiled-coil domain-containing proteins (CCDCs) are expressed in many cancers, but the role of Coiled-coil domain-containing protein 103 (CCDC103) in cancers remains unclear. Further investigations are necessary to ascertain its diagnostic significance and understand its biological function in cancers. This study aims to elucidate the biological functionalities of CCDC103 in glioma and evaluate the correlation between CCDC103 expression with glioma progression. METHODS: Clinical data on glioma patients were acquired from The Cancer Genome Atlas (TCGA), the Chinese Glioma Genome Atlas (CGGA), and the Gene Expression Omnibus (GEO). The evaluation encompassed the examination of correlations between CCDC103 expression, pathological characteristics, and clinical outcomes. Furthermore, the analysis included the assessment of the correlations between CCDC103 expression and immune cell infiltration as well as glioma progression. RESULTS: Gliomas have higher levels of CCDC103 expression than the para-carcinoma tissues. Poorer prognosis, unfavorable histological characteristics, the absence of IDH gene mutations, and the absence of chromosome 1p and 19q deletions were all associated with higher expression of CCDC103 in gliomas. In addition to patient age, tumor grade, the absence of IDH mutations, and the absence of chromosome 1p and 19q deletions, univariate and multivariate Cox analyses showed that CCDC103 expression was independently prognostic of overall survival, disease-free survival, and progression-free survival in patients with glioma. Furthermore, tumor infiltration of B cells, neutrophils, macrophages, and dendritic cells were all linked with elevated expression of CCDC103. High CCDC103 expression was linked to immune response-related signaling pathways and cell proliferation, according to gene set enrichment analysis (GSEA). Notably, the knockdown of CCDC103 in glioma cell lines resulted in a significant reduction in cell proliferation and migration. CONCLUSION: The correlation between CCDC103 expression and both glioma progression and immune cell infiltration implies that CCDC103 expression holds promise as a valuable prognostic biomarker for glioma. Dove 2023-10-18 /pmc/articles/PMC10590567/ /pubmed/37873495 http://dx.doi.org/10.2147/OTT.S429958 Text en © 2023 Xu et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Xu, Zhixing
Xu, Haitao
Chen, Xi
Huang, Xiaobing
Tian, Jintao
Zhao, Jinxi
Liu, Bohu
Shi, Fengcai
Wu, Jin
Pu, Jun
CCDC103 as a Prognostic Biomarker Correlated with Tumor Progression and Immune Infiltration in Glioma
title CCDC103 as a Prognostic Biomarker Correlated with Tumor Progression and Immune Infiltration in Glioma
title_full CCDC103 as a Prognostic Biomarker Correlated with Tumor Progression and Immune Infiltration in Glioma
title_fullStr CCDC103 as a Prognostic Biomarker Correlated with Tumor Progression and Immune Infiltration in Glioma
title_full_unstemmed CCDC103 as a Prognostic Biomarker Correlated with Tumor Progression and Immune Infiltration in Glioma
title_short CCDC103 as a Prognostic Biomarker Correlated with Tumor Progression and Immune Infiltration in Glioma
title_sort ccdc103 as a prognostic biomarker correlated with tumor progression and immune infiltration in glioma
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590567/
https://www.ncbi.nlm.nih.gov/pubmed/37873495
http://dx.doi.org/10.2147/OTT.S429958
work_keys_str_mv AT xuzhixing ccdc103asaprognosticbiomarkercorrelatedwithtumorprogressionandimmuneinfiltrationinglioma
AT xuhaitao ccdc103asaprognosticbiomarkercorrelatedwithtumorprogressionandimmuneinfiltrationinglioma
AT chenxi ccdc103asaprognosticbiomarkercorrelatedwithtumorprogressionandimmuneinfiltrationinglioma
AT huangxiaobing ccdc103asaprognosticbiomarkercorrelatedwithtumorprogressionandimmuneinfiltrationinglioma
AT tianjintao ccdc103asaprognosticbiomarkercorrelatedwithtumorprogressionandimmuneinfiltrationinglioma
AT zhaojinxi ccdc103asaprognosticbiomarkercorrelatedwithtumorprogressionandimmuneinfiltrationinglioma
AT liubohu ccdc103asaprognosticbiomarkercorrelatedwithtumorprogressionandimmuneinfiltrationinglioma
AT shifengcai ccdc103asaprognosticbiomarkercorrelatedwithtumorprogressionandimmuneinfiltrationinglioma
AT wujin ccdc103asaprognosticbiomarkercorrelatedwithtumorprogressionandimmuneinfiltrationinglioma
AT pujun ccdc103asaprognosticbiomarkercorrelatedwithtumorprogressionandimmuneinfiltrationinglioma